FHFabiana de Campos Cordeiro Hirata

Fabiana de Campos Cordeiro Hirata

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fabiana de Campos Cordeiro Hirata has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Quality assessment of clinical practice in neuro-oncology

    by Renata Carolina Acri Nunes Miranda, Suzana Maria Fleury Malheiros, André Felix Gentil, Gisele Sampaio Silva, Fabiana de Campos Cordeiro Hirata, Sérgio Eduardo Alonso Araujo, Luís Otávio Sales Caboclo

    Highlights ■ The molecular test according to the WHO classification of CNS tumors (gliomas) was performed in 100% (172) of patients. ■ Education on chemotherapy and informed consent for patients with brain tumors was carried out for 100% (130) of the patients who had an indication for chemotherapy treatment. ■ Approximately 87% of the patients with gliomas underwent postoperative cranial MRI. ■ A multidisciplinary approach, including molecular testing, was used for 35% of patients with glioma. ■ Thromboembolic events after

  • Open Access

    Advances in diffuse glial tumors diagnosis

    by Luis Filipe de Souza Godoy, Vitor Ribeiro Paes, Aline Sgnolf Ayres, Gabriela Alencar Bandeira, Raquel Andrade Moreno, Fabiana de Campos Cordeiro Hirata, Frederico Adolfo Benevides Silva, Felipe Nascimento, Guilherme de Carvalho Campos Neto, Andre Felix Gentil, et al.

    In recent decades, there have been significant advances in the diagnosis of diffuse gliomas, driven by the integration of novel technologies. These advancements have deepened our understanding of tumor oncogenesis, enabling a more refined stratification of the biological behavior of these neoplasms. This progress culminated in the fifth edition of the WHO classification of central nervous system (CNS) tumors in 2021. This comprehensive review article aims to elucidate these advances within a multidisciplinary framework, contextualized within the backdrop of the new classification. This article will explore morphologic pathology and molecular/genetics techniques (immunohistochemistry, genetic sequencing, and methylation profiling), which are pivotal in diagnosis, besides the correlation of structural neuroimaging radiophenotypes to pathology and genetics. It briefly reviews the usefulness of tractography and functional neuroimaging in surgical planning. Additionally, the article addresses the value of other functional imaging techniques such as perfusion MRI, spectroscopy, and nuclear medicine in distinguishing tumor progression from treatment-related changes. Furthermore, it discusses the advantages of evolving diagnostic techniques in classifying these tumors, as well as their limitations in terms of availability and utilization. Moreover, the expanding domains of data processing, artificial intelligence, radiomics, and radiogenomics hold great promise and may soon exert a substantial influence on glioma diagnosis. These innovative technologies have the potential to revolutionize our approach to these tumors. Ultimately, this review underscores the fundamental importance of multidisciplinary collaboration in employing recent diagnostic advancements, thereby hoping to translate them into improved quality of life and extended survival for glioma patients.